Cancer Family
Malignant Breast Neoplasm
CI-CAN-00000227Explore in graph →
Top-level2,628 active trials43 approved drugs310 evidence items
- NCIt
- C9335
- ICD-10
- C50
- DOID
- 1612
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000227Explore in graph →
Clinical trials
12,359 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,368)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07829848 | Response-Adapted Omission of Nodal Boost In N3 Breast Cancer After Neoadjuvant Systemic Therapy | recruiting | N/A | 534 | Fudan UniversityOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT07835698 | The Validation of ICBT Clinical Trial: Disease Stress Adjustment in Breast Cancer Patients(ICBT-TW-2) | not yet recruiting | N/A | 100 | National Health Research Institutes, TaiwanOTHER | 0 | Sep 23, 2026 | clinicaltrials |
| NCT07836257 | A Phase II Study of Trastuzumab Deruxtecan (T-DXd) Plus Pyrotinib in HER2-Positive Advanced Breast Cancer After Progression on T-DXd | not yet recruiting | Phase 2 | 28 | Fujian Medical UniversityOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT01174121 | Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer | recruiting | Phase 2 | 332 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT03766009 | Increasing Patients' Engagement in Breast Cancer Surgery Decision-Making | active not recruiting | N/A | 627 | Alliance for Clinical Trials in OncologyOTHER | 3 | Sep 22, 2026 | clinicaltrials |
| NCT04994067 | Intra-Operative Radiation Registry | recruiting | — | 460 | Albert Einstein College of MedicineOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT05422794 | Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer | recruiting | Phase 1 | 57 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT06085833 | ARTIDIS Nanomechanical Generated Measurements for Early Breast Lesions(ANGEL) | recruiting | N/A | 2,706 | ARTIDIS AGINDUSTRY | 3 | Sep 22, 2026 | clinicaltrials |
| NCT06714617 | Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors | terminated | Phase 1 | 3 | SystImmune Inc.INDUSTRY | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07426913 | Cardiovascular Health Education Via Virtual Reality for Breast Cancer Survivors Receiving Anthracyclines or Trastuzumab | recruiting | N/A | 30 | Virginia Commonwealth UniversityOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07528768 | HEADWATERS: Gemcitabine vs Paclitaxel in Metastatic Triple-Negative Breast Cancer in Women of African Ancestry. | not yet recruiting | Phase 2 | 750 | The University of The West IndiesOTHER | 3 | Sep 22, 2026 | clinicaltrials |
| NCT07614620 | Effect of Hypnosis in the Management of Anxiety and Chemo-induced Symptoms in Adolescents and Young Adults With Sarcoma or Germ Cell Tumor and in Young Women With Breast Cancer(HYPNO-AJA2) | recruiting | N/A | 70 | Institut BergoniéOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07619365 | Trastuzumab Deruxtecan and Lovastatin in HER2-low and Ultralow Advanced or Metastatic Breast Cancer | not yet recruiting | Phase 2 | 60 | Washington University School of MedicineOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07770243 | AI-Based Symptom Management for Post-Treatment Breast Cancer Survivors(AIMS-BC) | not yet recruiting | N/A | 36 | Hong Kong Metropolitan UniversityOTHER | 0 | Sep 22, 2026 | clinicaltrials |
| NCT07801508 | A Study of [68Ga]Ga-DWJ155 in Adult Patients With Solid Tumors | recruiting | Phase 1 | 66 | Novartis PharmaceuticalsINDUSTRY | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07833085 | CAIX-targeted PET/CT in Solid Tumors(CAIX-PET) | not yet recruiting | N/A | 100 | Zhongnan HospitalOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07833566 | Biopsy-site-marker in Breast Cancer | recruiting | — | 140 | University of OklahomaOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07833891 | Senocohort: Identification of Predictive Biomarkers in Breast Cancer Treatment(SENOCOHORT) | not yet recruiting | — | 500 | Assistance Publique - Hôpitaux de ParisOTHER | 0 | Sep 22, 2026 | clinicaltrials |
| NCT07835139 | Hypofractionated vs. Conventionally Fractionated Postmastectomy Radiotherapy After Implant-Based Reconstruction | recruiting | N/A | 534 | Fudan UniversityOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT02620852 | Women Informed to Screen Depending on Measures of Risk (Wisdom Study)(WISDOM) | recruiting | N/A | 100,000 | University of California, San FranciscoOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT03357120 | Circulating Tumor DNA After Neoadjuvant Chemotherapy(ALIENOR) | completed | N/A | 120 | Institut BergoniéOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT03455270 | G1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast Cancer | completed | Phase 1 | 107 | G1 Therapeutics, Inc.INDUSTRY | 7 | Sep 21, 2026 | clinicaltrials |
| NCT04084730 | Study of 3-Day Partial Breast Radiation Therapy in Women With Breast Cancer | recruiting | Phase 2 | 280 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT04644068 | Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies(PETRA) | active not recruiting | Phase 1 / Phase 2 | 702 | AstraZenecaINDUSTRY | 14 | Sep 21, 2026 | clinicaltrials |
| NCT04734262 | A Phase II Study to Explore the Safety, Tolerability, and Preliminary Antitumor Activity of Sitravatinib Plus Tislelizumab or Combination With Nab-paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)(SPARK) | active not recruiting | Phase 2 | 98 | Fudan UniversityOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT05377047 | Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer(TAORMINA) | recruiting | Phase 3 | 345 | Vastra Gotaland RegionOTHER_GOV | 6 | Sep 21, 2026 | clinicaltrials |
| NCT05550415 | The Role of Simvastatin in The Epithelial-Mesenchymal Transition Process of Breast Cancer | recruiting | Phase 2 | 26 | Universitas IndonesiaOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT05894239 | A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer(INAVO122) | recruiting | Phase 3 | 230 | Hoffmann-La RocheINDUSTRY | 29 | Sep 21, 2026 | clinicaltrials |
| NCT05983432 | Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors | recruiting | Phase 1 | 540 | SystImmune Inc.INDUSTRY | 5 | Sep 21, 2026 | clinicaltrials |
| NCT06137833 | Wide Spectrum Micronutrients Supplementation in Patients With Cancer Related Fatigue During Neoadjuvant and Adjuvant Chemotherapy | completed | N/A | 92 | Pharmanutra S.p.a.INDUSTRY | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06411678 | Application of 68GA-labeled CD73 Targeting Probe PET/CT Imaging in the Diagnosis of Breast Cancer | recruiting | Early Phase 1 | 50 | Peking Union Medical College HospitalOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07338721 | Does Ultrasound Guidance Axillary Incision Improve Sentinel Lymph Node Detection in Breast Cancer? | completed | — | 100 | Antalya Training and Research HospitalOTHER_GOV | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07524855 | A Study of JNJ-101684362 (HLD-0117) in Patients With Metastatic Breast Cancer(HLD-0117) | recruiting | Phase 1 | 170 | Janssen Research & Development, LLCINDUSTRY | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07829900 | First-Line Dual Versus Single HER2-Targeted Therapy With Docetaxel for Advanced HER2-Positive Breast Cancer | completed | — | 2,250 | Xin LiOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07831460 | Horse-assisted Interventions in an Oncological Centre(ISACCO) | completed | N/A | 28 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07831889 | Hypofractionated Radiotherapy After Breast Reconstruction for Breast Cancer | not yet recruiting | N/A | 960 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Sep 21, 2026 | clinicaltrials |
| NCT01334021 | Genetic Testing in Predicting Tumor Response in Patients With Stage I-III HER2 Negative Invasive Breast Cancer | active not recruiting | Phase 2 | 1,100 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT01872260 | Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer | active not recruiting | Phase 1 / Phase 2 | 259 | Novartis PharmaceuticalsINDUSTRY | 8 | Sep 18, 2026 | clinicaltrials |
| NCT02221700 | Massage Therapy in Reducing Chemotherapy-Induced Peripheral Neuropathy in Patients With Gastrointestinal or Breast Malignancies | active not recruiting | N/A | 90 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT02455791 | Feasibility and Identification of Breast Cancer Patients for Potential Avoidance of Surgery | active not recruiting | N/A | 43 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT03796559 | Magseed Enabled Long-Term Localization of Axillary Lymph Nodes(MAGELLAN) | recruiting | N/A | 65 | Endomagnetics Ltd.INDUSTRY | 1 | Sep 18, 2026 | clinicaltrials |
| NCT04038619 | Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients | recruiting | Phase 1 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT04090398 | Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer That Has Spread to the Bones | active not recruiting | Phase 2 | 70 | National Cancer Institute (NCI)NIH | 1 | Sep 18, 2026 | clinicaltrials |
| NCT04524000 | Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer | active not recruiting | Phase 2 | 24 | Novartis PharmaceuticalsINDUSTRY | 1 | Sep 18, 2026 | clinicaltrials |
| NCT04638751 | ARGONAUT: Stool and Blood Sample Bank for Cancer Patients | suspended | — | 5,000 | Persephone BiosciencesINDUSTRY | 1 | Sep 18, 2026 | clinicaltrials |
| NCT04871139 | An Imaging Technology, Contrast-Enhanced Mammography, in Predicting Breast Cancer | active not recruiting | N/A | 100 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT05161195 | Roll-over Study to Allow Continued Access to Ribociclib | active not recruiting | Phase 4 | 134 | Novartis PharmaceuticalsINDUSTRY | 22 | Sep 18, 2026 | clinicaltrials |
| NCT06512350 | Identifying Patterns in the Breath of Individuals With Breast Cancer | recruiting | — | 5,175 | Breathe BioMedical IncINDUSTRY | 2 | Sep 18, 2026 | clinicaltrials |
| NCT06560385 | Alleviation of Alopecia in Breast Cancer Patient Using Synbiotics Formula | terminated | N/A | 7 | GenieBiome LimitedINDUSTRY | 1 | Sep 18, 2026 | clinicaltrials |
| NCT06746688 | A First-in-human, Clinical Trial Assessing the Safety of ES2B-C001-S01 With or Without [Adjuvant] in Patients With HER2-expressing Metastatic Breast Cancer. | active not recruiting | Phase 1 | 40 | ExpreS2ion BiotechnologiesINDUSTRY | 1 | Sep 18, 2026 | clinicaltrials |
Data updated 5 days agoSource updated Sep 23, 2026source: clinicaltrials